This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"5 Key Considerations for Valuing PharmaCompanies As the pharmaceutical industry continues to evolve, accurately valuing pharmacompanies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. These innovations have started to shift industry perceptions, positioning AI as a transformative tool that could alter how drugs are developed, tested, and brought to market.
Trillion Wake-Up Call for the Pharmaceutical Industry As the pharmaceutical landscape continues to shift, one thing is clear: the expiration of drug patents is no longer a footnote in the industry's financials. But what does this mean for pharmacompanies, investors, and patients? "Patent Expiration: The $1.4
"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way PharmaCompanies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.
Market conditions like this are demoralizing in the worst way. We had a significantly limited set of Phase 1B data in psoriasis patients for TYK2 at the time, and we were now free to speak to pharmacompanies interested in our TYK2 program. By any measure, 2023 so far has seen some of the worst performance in biotech (e.g.,
Pharmaceuticalcompanies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3
Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.
Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation.
Drive Engagement and Segmentation for Physician Marketing With the proliferation of digital media, marketing in the healthcare industry has shifted from traditional tactics to an omnichannel approach. With an omnichannel approach, pharmamarketers can have a better understanding of HCP interests and preferences.
The cost to develop a new prescription medicine that gains market approval has gone up 145% to $2.6 It is reported that every one of the major pharmaceuticalcompanies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? Nature , vol.
.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., Vickers has over 30 years of experience as a researcher and leader in the pharmaceutical industry.
This effort seeks to provide the pharmaceutical industry with more accurate representation of patient populations, thereby enhancing the safety and efficacy for prescription drugs and medical devices. Hence, pharmaceuticalcompanies need to start making preparations to ensure compliance with the new requirements.
“Our ambition is to become the first pharmacompany powered by artificial intelligence at scale, giving our people tools and technologies that focus on insights and allow them to make better everyday decisions. … Learn more about LAICA RepAssist by ACTO – the only AI Knowledge Assistant built for pharma field reps!
Drug Pricing, Global Diversity Strategies, & Emerging AI Applications Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the year ahead.
Ensuring access to safe and effective treatments is the main challenge faced by pharmaceuticalcompanies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine?
This week, another pharmacompany revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose. Save your seat at IDBS’s upcoming webinar.
Since KOLs play such a critical role, engaging with the right KOLs is a key strategy for pharmaceuticalcompanies to stay ahead of the game. Compliance ensures that interactions between pharmaceuticalcompanies and KOLs are transparent, fair, and free from any undue influence.
Because pharmacompanies can’t predict which early-stage drug candidates will succeed, they end up playing a “numbers game,” according to Bush, by advancing multiple compounds. What happens if we are able to provide information to the pharmaceuticalcompany that doubles that [and] one in 10 molecules actually make it?”
During his tenure, Evotec established itself as a leading drug discovery and development company with a particular focus on precision medicine through early adoption of paradigm-shifting technologies such as iPSC-based drug discovery, industrialised multi-omics, and artificial intelligence-driven data analytics throughout the drug discovery process.
Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. We have a cell trapper moiety that traps it inside the cell. Rich McCormick: That’s impressive teamwork.
Since Arvinas’ findings, another company, Kymera Therapeutics, showed that a protein-destroying medicine it developed may be able to stifle a drug target others have struggled to reach. Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins.
Daniel Galbraith, Chief Scientific Officer at Solvias , brings extensive expertise in the pharmaceutical and biotechnology sectors. In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry.
However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharmacompany. I experienced challenges in cultural differences working with US, UK, Japan, and China.
AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceuticalcompany Amomed and the Luxembourgish health-tech company SciPharm. Talking Medicine uses advanced AI to provide pharmaceuticalcompanies with real-time data intelligence. Growth Programme. Dolmatics – U.K.-based Source link.
A single pill also is cheaper to market and distribute. Yang pointed out that “the fact that it’s generic is a double-edged sword, because no big pharmacompany is willing to invest a lot of money in developing and marketing a polypill. If it’s more convenient together, why not?”
3 Another considerable obstacle to pharmaceuticalcompanies’ interest (and investment) is the fact that for a product to be patentable — and therefore profitable — it has to be considered new and inventive. 4 But the same barriers still exist today.
Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). By geographical region, the global CRO services market in 2023 was dominated by North America. As a result, the global CRO market is estimated to grow at a compound annual growth rate (CAGR) of 9.6%
Before I show you what this breakthrough pain solution is, I want to let you in on the “dirty little secret” of the pharmaceutical industry. ” Here’s The Dirty Little Secret Of The Pharmaceutical Industry. Why did the big pharmaceuticals maker under express or hide the potential for addictions with opiates.
“Our ambition is to become the first pharmacompany powered by artificial intelligence at scale, giving our people tools and technologies that focus on insights and allow them to make better everyday decisions. … Learn more about LAICA RepAssist by ACTO – the only AI Knowledge Assistant built for pharma field reps!
The operational impact of xAI is substantial, especially given that 37 percent of the market views the explanation of results from GenAI algorithms as a strategic priority that goes beyond regulatory compliance. Techbio companies have initiated this approach.
market first, based on an evaluation by the independent board members.
Another Biden plan opens up foreign markets for consumers to buy their prescription drugs and calls for limiting price increases on branded drugs and generics for drugs included in the Medicare program. They are:
• BioMarin Pharmaceutical.
Including the pharmaceutical corporation’s wallet-sucking chemical solutions. I know I’m not going to reach as many men as the Big Pharmacompanies with 100 Million Dollar advertising budgets…. It took me over 100 hours to go through the available studies and discover which foods had the most promise….
The law made it less likely for pharmacompanies to pursue more rare disease indications, according to industry groups such as the National Pharmaceutical Council. Currently, the program exempts orphan drugs from price negotiations if they only have one use for rare disease. By Jacob Bell • May 6, 2025 Keep up with the story.
We observed oral argument the other day in a case that could have a significant impact on potential liability under California tort law for pharmacompanies and all other innovators. As plaintiffs who took the TDF medicines, their claims are about the defendant’s failure to develop more quickly and market faster the later drug, TAF.
The case is Vanda Pharmaceuticals, Inc. 27, 2023), and the plaintiff was a pharmaceuticalcompany that wanted to know what the FDA really thought of its drug. The company lodged a request under the Freedom of Information Act (“FOIA”), which the FDA refused. 22-cv-938, 2023 U.S. LEXIS 51853 (D.D.C. Here is what happened.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content